Apellis Pharmaceuticals I... (APLS)
NASDAQ: APLS
· Real-Time Price · USD
28.31
-0.34 (-1.19%)
At close: Sep 05, 2025, 10:06 AM
-1.19% (1D)
| Bid | 28.31 |
| Market Cap | 3.58B |
| Revenue (ttm) | 754.65M |
| Net Income (ttm) | -228.17M |
| EPS (ttm) | -1.89 |
| PE Ratio (ttm) | -14.98 |
| Forward PE | -31.24 |
| Analyst | Hold |
| Ask | 28.38 |
| Volume | 459,031 |
| Avg. Volume (20D) | 2,312,445 |
| Open | 28.84 |
| Previous Close | 28.65 |
| Day's Range | 28.16 - 28.97 |
| 52-Week Range | 16.10 - 41.94 |
| Beta | 0.77 |
About APLS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol APLS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for APLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Apellis Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+17.58%
Apellis Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
1 month ago
+1.07%
APLS stock has given up its prior gain. Apellis Pharmaceuticals shares were trading higher after the company announced it has won FDA approval for EMPAVELI.
1 month ago · seekingalpha.com
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call TranscriptApellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Caroline R. Baumal - Chief Medical Officer Cedric Francois - Co-Founder, Pre...
